UK doctors look back at real-world use of new VWD drug

NCT ID NCT06433778

Completed Knowledge-focused Sponsor: Takeda Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at medical records of 34 adults with von Willebrand disease (VWD) in the UK who received a newer treatment called vonicog alfa (rVWF). The goal was to see how well it controlled bleeding and was used during surgeries in real-world settings. No new treatments or tests were given; researchers simply collected existing data from routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VON WILLEBRAND DISEASE (VWD)

Contacts and locations

Locations

Imperial College Healthcare

London, W2 1NY, United Kingdom
Leeds Teaching Hospital

Leeds, LS9 7TF, United Kingdom
Liverpool University Hospital

Liverpool, L7 8XP, United Kingdom
Manchester University

Manchester, M13 9WL, United Kingdom
Oxford University Hospital

Oxford, OX3 9DU, United Kingdom
Royal Free London

London, NW3 2QG, United Kingdom
University Hospitals Birmingham

Birmingham, B15 2GW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.